Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
复方薏薢颗粒
- Development stage
- Phase 2
- Lead developer
- Humanwell Healthcare
- Administration
- Oral
01
Overview
复方薏薢颗粒 (Fufang Yixie Keli) is a traditional Chinese medicine (TCM) oral granule developed by Wuhan Humanwell Hi-Tech Industry. It is specifically indicated for the treatment of non-acute gout and hyperuricemia in patients presenting with the TCM syndrome of dampness-turbidity-stasis obstruction (湿浊瘀阻证). The formulation is designed to lower serum uric acid levels and prevent gout flares by addressing the underlying TCM pathology of dampness and blood stasis. It is currently in Phase 3 clinical trials in China.
- Other names
- Compound Yiba GranulesFufang Yixie KeliCompound Yixie Granules
Beyond the preview
Go deeper on 复方薏薢颗粒.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 复方薏薢颗粒.